SCHEMBL3522266

SCHEMBL3522266

Cc1noc(C)c1CN1CCOC(C(=O)N(Cc2ccc3c(c2)OCCCO3)CC(C)C)C1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PROKR2 Q8NFJ6 4/20 0.55
ALDH1A1 P00352 2/20 0.39
MAPK1 P28482 2/20 0.39
TAS2R8 Q9NYW2 5/20 0.39
SMN1; SMN2 Q16637 3/20 0.37
KDM4E B2RXH2 2/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPT P10636 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
GAA P10253 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GRN P28799 1/20 0.34
SORT1 Q99523 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3516521 0.87 PROKR2 (0.54) PROKR2ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL3522211 0.86 PROKR2 (0.56) PROKR2ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL3516858 0.86 PROKR2 (0.56) PROKR2ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL3518160 0.85 PROKR2 (0.62) PROKR2ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL387975 0.85 PROKR2 (0.63) PROKR2ALDH1A1KDM4EKMT2AGAA
SCHEMBL3517508 0.85 PROKR2 (0.63) PROKR2ALDH1A1KDM4EKMT2AGAA
SCHEMBL3516623 0.85 PROKR2 (0.63) PROKR2ALDH1A1KDM4EKMT2AGAA
SCHEMBL3520053 0.84 PROKR2 (0.57) PROKR2ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL3516808 0.84 PROKR2 (0.56) PROKR2ALDH1A1MAPK1SMN1; SMN2KDM4E
SCHEMBL3519332 0.84 PROKR2 (0.54) PROKR2ALDH1A1SMN1; SMN2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1959959-B1 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-04-10 EP claimed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US claimed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US claimed
EP-1959959-B1 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-04-10 EP disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists PROKR2, PROKR1, NTSR2 PROKR2 1/4885ALDH1A1 4629/4885MAPK1 1374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.